Skip to content
OpenCapital
Get started

Exelixis EXEL AFS and Trading Securities - Unrealized Loss Position (>=12 Months)

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's afs and trading securities - unrealized loss position (>=12 months).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's AFS and trading securities - unrealized loss position (>=12 months)?
Exelixis (EXEL) reported AFS and trading securities - unrealized loss position (>=12 months) of $7.94M in Q1 2026.
How has Exelixis's AFS and trading securities - unrealized loss position (>=12 months) changed year-over-year?
Exelixis's AFS and trading securities - unrealized loss position (>=12 months) decreased by 95.4% year-over-year, from $171.78M to $7.94M.
What is the long-term trend for Exelixis's AFS and trading securities - unrealized loss position (>=12 months)?
Over 3 years (2022 to 2025), Exelixis's AFS and trading securities - unrealized loss position (>=12 months) has grown at a -65.1% compound annual growth rate (CAGR), from $237.6M to $10.1M.